Adventrx Pharmaceuticals: Primed to Jump or Drop?
Tony Pelz submits:
I have been doing my monthly review of a couple hundred small-cap biotech companies and took a closer look at ADVENTRX Pharmaceuticals (ANX). According to the company’s website:
ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are being developed to improve the performance of existing anti-cancer drugs by addressing limitations associated principally with their safety and use. Its lead product candidates include ANX-530, an emulsion formulation of chemotherapy drug vinorelbine to treat advanced non-small cell lung cancer as a single agent or in combination with cisplatin, as well as to treat advanced or metastatic breast cancer and ANX-514, an emulsion formulation of the chemotherapy drug docetaxel for the treatment of breast, non-small cell lung, prostate, gastric, and head and neck cancers.
Complete Story »
View full post on Seeking Alpha Small Cap stocks
